Phase
Condition
Liver Disease
Treatment
HuHuangLianzonggan capsule placebo
HuHuangLianzonggan capsule
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Males and females between 18-75 years of age inclusive(including boundary values).
Must have had a liver biopsy proven NASH within 6 months or in screening test. Thefollowing two requirements must be met at the same time: ① a non-alcoholic fattyliver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in eachof the following NAS components: Steatosis≥1, Lobular inflammation≥1, Ballooningdegeneration≥1;② fibrosis stage 1 to 3.
Must have confirmation of ≥ 8% liver fat content on magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at screening.
No alcohol consumption or history of excessive alcohol consumption: less than 210 gof ethanol per week for men and 140 g for women in the past 12 months.
Patients who are taking chronic drugs(including but not limited to antihypertensivedrugs, antiatherogenic drugs, oral hypoglycemic drugs, insulin) need to have asteady dose for at least 3 months before liver biopsy.
Weight was stable(the change is no more than 5%) during the 6 months prior toScreening.
No attempt to change lifestyle (diet and/or exercise) during the 3 months prior toScreening.
Ability to understand the requirements of the study and willingness to providewritten informed consent.
Have no pregnancy program and take effective contraceptive measures voluntarily.
Abide by the experimental protocol and cooperate with the data collection accordingto the researcher's judgment.
Exclusion
Exclusion Criteria:
Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD)administered for at least 2 weeks within 12 months prior to qualifying liver biopsy (e.g. valproic acid, tamoxifen, methotrexate, amiodarone, oral corticosteroids, >5mg/day of prednisone equivalent [one short (<2 weeks) course of oralcorticosteroids, more than 3 months before the liver biopsy is allowed], oroestrogens [at doses greater than those used for contraception or hormonereplacement]).
Documented causes of fatty liver disease other than NASH including, but notrestricted to: HCV-associated fatty liver (genotype 3), hepatolenticulardegeneration, autoimmune hepatitis, total parenteral nutrition,abetalipoproteinemia, lipoatrophy , Coeliac disease, Primary sclerosing cholangitis,Alpha-1-antitrypsin deficiency, Drug-induced liver disease.
Model for End-stage Liver Disease (MELD) score >12.
Histologically documented liver cirrhosis (fibrosis stage F4), history or currentdiagnosis of hepatocellular carcinoma HCC.
History of or planned liver transplant.
Viral hepatitis:Positive hepatitis A antibody,Positive hepatitis D antibody,Positivehepatitis E antibody,Positive hepatitis B surface antigen (HBsAg) ,Positivehepatitis C antibody.
Abnormal liver function as defined by Screening central laboratory evaluation of anyof the following: ALT or AST >5 × ULN; Alkaline phosphatase (ALP) >2 × ULN; albuminbelow the lower limit of the normal range; total bilirubin level >1.5 × ULN (patients with a documented history of Gilbert's syndrome can be enrolled if thedirect bilirubin is within normal reference range).
In patients who are not anticoagulated, INR ≥ 1.3 times ULN or other evidence ofimpaired coagulation.
Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value <30mL/min/1.73 m2.
Patient currently receiving any approved treatment for NASH.
HbA1c ≥9% or fasting blood-glucose>13.9 mmol/L at Screening.
Diabetes mellitus other than type 2 (e.g. type 1, diabetes caused by drugs orchemicals, and immune-mediated diabetes).
Those who are underweight, of normal weight, or severely obese, i.e BMI<23 kg/m2 orBMI≥40 kg/m2.
Bariatric surgery or tumor surgery are not allowed within 5 years of the qualifyingliver biopsy.
Uncontrolled hypertension (values ≥160/100 mm Hg) or hypotension(values <80/50mmHg).
Acute vascular events including ACS, stroke, peripheral vascular disease worsened,or any vascular/cardiac surgery within the 6 months prior to Screening.
Concomitant mental illness and poor condition control, which affects the signing ofinformed consent or presentation of adverse events.
Do not have a liver biopsy within the 6 months prior to Screening and refuse to takeliver biopsy at Screening.
Allergic constitution, or allergic to the test drug or its ingredients.
Women who are pregnant or lactating.
Participate in clinical trials of other drugs within 3 months before screening.
The researchers did not consider it appropriate to participate in this study.
Study Design
Connect with a study center
Anhui Provincial Hospital
Hefei, Anhui
ChinaSite Not Available
The Second Hospital of Anhui Medical University
Hefei, Anhui
ChinaSite Not Available
Peking University Third Hospital
Beijing, Beijing
ChinaActive - Recruiting
The first affiliated hospital of Fujian medical university
Fuzhou, Fujian
ChinaSite Not Available
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong
ChinaSite Not Available
The Third People's Hospital of Shenzhen
Shenzhen, Guangdong
ChinaActive - Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan
ChinaActive - Recruiting
Shiyan renmin hospital
Shiyan, Hubei
ChinaSite Not Available
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei
ChinaActive - Recruiting
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu
ChinaActive - Recruiting
The Affiliated Hospital of Nanjing University medical school,Nanjing Drum Tower Hospital
Nanjing, Jiangsu
ChinaSite Not Available
The Second Hospital of Nanjing
Nanjing, Jiangsu
ChinaActive - Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu
ChinaActive - Recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia
ChinaSite Not Available
Sichuan Provincial People's Hospital
Chengdu, Sichuan
ChinaActive - Recruiting
Tianjin Second People's Hospital
Tianjin, Tianjin
ChinaActive - Recruiting
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang
ChinaActive - Recruiting
Ningbo Huamei Hospital, University of Chinese Academy of Sciences
Ningbo, Zhejiang
ChinaActive - Recruiting
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang
ChinaActive - Recruiting
Taizhou Municipal Hospital
Taizhou, Zhejiang
ChinaActive - Recruiting
Rui'an People's Hospital
Wenzhou, Zhejiang
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.